169 related articles for article (PubMed ID: 28082339)
1.
Byun JM; Koh Y; Shin DY; Kim I; Yoon SS; Lee JO; Bang SM; Kim KH; Jung SH; Lee WS; Park Y; Jang JH; Han JJ; Yhim HY; Kim DS; Lee YJ; Lee H; Choi YS; Lee S;
Haematologica; 2017 May; 102(5):e187-e190. PubMed ID: 28082339
[No Abstract] [Full Text] [Related]
2. Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed/refractory acute lymphoblastic leukemia.
Hanif A; Wang ES; Thompson JE; Baron JI; Walsh MD; Griffiths EA
Leuk Lymphoma; 2018 Aug; 59(8):2011-2013. PubMed ID: 29251203
[No Abstract] [Full Text] [Related]
3. Reaping the benefits of recent advances for adults with acute lymphoblastic leukemia.
Brown PA; Alvarnas JC
J Natl Compr Canc Netw; 2012 Jul; 10(7):800-1. PubMed ID: 22773795
[No Abstract] [Full Text] [Related]
4. Philadelphia-positive Acute Lymphoblastic Leukemia: Do We Still Need Allogeneic Transplantation? Argument "Pro".
Bachanova V
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S10-S15. PubMed ID: 28760293
[No Abstract] [Full Text] [Related]
5. Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.
Leoni V; Biondi A
Haematologica; 2015 Mar; 100(3):295-9. PubMed ID: 25740105
[No Abstract] [Full Text] [Related]
6. Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.
Abou Dalle I; Kantarjian HM; Short NJ; Konopleva M; Jain N; Garcia-Manero G; Garris R; Qiao W; Cortes JE; O'Brien S; Kebriaei P; Kadia T; Jabbour E; Ravandi F
Am J Hematol; 2019 Dec; 94(12):1388-1395. PubMed ID: 31595534
[TBL] [Abstract][Full Text] [Related]
7. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].
Wang J; Huang X; Jiang B; Qin Y; Bao L; Jiang H; Chen H; Jia J; Yang S; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):120-5. PubMed ID: 24606652
[TBL] [Abstract][Full Text] [Related]
8. Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates.
Boer JM; Koenders JE; van der Holt B; Exalto C; Sanders MA; Cornelissen JJ; Valk PJ; den Boer ML; Rijneveld AW
Haematologica; 2015 Jul; 100(7):e261-4. PubMed ID: 25769542
[No Abstract] [Full Text] [Related]
9. Emerging BCR/ABL1 Mutations Under Treatment with Tyrosine Kinase Inhibitors in Paediatric Acute Lymphoblastic Leukaemia.
Molinos-Quintana A; Aquino V; Montero I; Pérez-de Soto C; García-Lozano R; Pérez-Simón JA; Pérez-Hurtado JM
Acta Haematol; 2015; 134(2):71-5. PubMed ID: 25895602
[TBL] [Abstract][Full Text] [Related]
10. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
11. Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia.
Šálek C; Folber F; Froňková E; Procházka B; Marinov I; Cetkovský P; Mayer J; Doubek M;
Eur J Haematol; 2016 Mar; 96(3):276-84. PubMed ID: 25997106
[TBL] [Abstract][Full Text] [Related]
12. BCR/ABL1 Kinase Domain Mutation Monitoring: Could Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Benefit As Well?
Andolina JR
Acta Haematol; 2015; 134(2):69-70. PubMed ID: 25895547
[No Abstract] [Full Text] [Related]
13. Different impact of BCR-ABL transcripts on allogeneic hematopoietic cell transplantation from different graft sources for Ph + ALL with minimal residual disease.
Nishiwaki S; Mizuta S; Ohashi K; Fukuda T; Uchida N; Tachibana T; Onizuka M; Ozawa Y; Onishi Y; Takahashi S; Eto T; Nakamae H; Tanaka J; Ichinohe T; Atsuta Y; Kako S;
Am J Hematol; 2019 Nov; 94(11):E301-E305. PubMed ID: 31403213
[No Abstract] [Full Text] [Related]
14. Clinical sensitivity to anthracyclines in PH/BCR+ acute lymphoblastic leukemia.
Bassan R; Rohatiner AZ; Rambaldi A; Lerede T; Di Bona E; Carter M; Rossi G; Pogliani E; Lambertenghi-Deliliers G; Fabris P; Porcellini A; Lister TA; Barbui T
Adv Exp Med Biol; 1999; 457():489-99. PubMed ID: 10500826
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.
Pfeifer H; Lange T; Wystub S; Wassmann B; Maier J; Binckebanck A; Giagounidis A; Stelljes M; Schmalzing M; Dührsen U; Wunderle L; Serve H; Brück P; Schmidt A; Hoelzer D; Ottmann OG
Leukemia; 2012 Jul; 26(7):1475-81. PubMed ID: 22230800
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients.
Soverini S; De Benedittis C; Papayannidis C; Polakova KM; Venturi C; Russo D; Bresciani P; Iurlo A; Mancini M; Vitale A; Chiaretti S; Foà R; Abruzzese E; Sorà F; Kohlmann A; Haferlach T; Baccarani M; Cavo M; Martinelli G
Leukemia; 2016 Jul; 30(7):1615-9. PubMed ID: 26867670
[No Abstract] [Full Text] [Related]
17. The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment.
Thomas X; Heiblig M
Expert Opin Drug Discov; 2016 Nov; 11(11):1061-1070. PubMed ID: 27548716
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
19. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
[TBL] [Abstract][Full Text] [Related]
20. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.
Martinelli G; Iacobucci I; Storlazzi CT; Vignetti M; Paoloni F; Cilloni D; Soverini S; Vitale A; Chiaretti S; Cimino G; Papayannidis C; Paolini S; Elia L; Fazi P; Meloni G; Amadori S; Saglio G; Pane F; Baccarani M; Foà R
J Clin Oncol; 2009 Nov; 27(31):5202-7. PubMed ID: 19770381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
